Anika Therapeutics (ANIK) Reports Q2 Loss, Tops Revenue Estimates
Anika Therapeutics (ANIK) came out with a quarterly loss of $0.13 per share in line with the Zacks Consensus Estimate. This compares to earnings of $0.17 per share a year ago. These figures are adjusted for non-recurring items. A quarter ago, it was expected that this medical technology company would post earnings of $0.09 per share when it actually produced a loss of $0.06, delivering a surprise of -166.67%. Over the last four quarters, the company has not been able to surpass consensus EPS estimates. Anik ...